Saurabh Saha - Feb 1, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Executive Officer, Director
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 05:30 PM
Previous filing
Nov 18, 2021
Next filing
Feb 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Share Option (right to buy) Award $0 +750K $0.00 750K Feb 1, 2022 Ordinary Shares 750K $9.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2022.
F2 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.